Novo Nordisk has announced an impressive 18% jump in sales for the first quarter, marking a significant achievement for the pharmaceutical company known for its obesity treatments. The operating profit reached 38.79 billion Danish crowns, equivalent to $5.90 billion, reflecting a 22% increase compared to the previous year. This financial success underscores the company's strong market presence and product demand, as reported by Reuters.
In light of recent performance, Novo Nordisk has revised its 2025 sales growth outlook to a range of 13% to 21%, which is a downshift from the earlier projection of 16% to 24%. Similarly, the operating profit growth forecast has been adjusted to 16% to 24%, compared to the previously estimated 19% to 27%. This revision comes amidst growing competition from compounded GLP-1 drugs in the U.S., affecting the market penetration of Novo Nordisk’s branded treatments.
CEO Lars Fruergaard Jørgensen addressed these changes, acknowledging the company's robust performance while highlighting market challenges that influenced the updated forecasts. Despite facing increased competitive pressures, Novo Nordisk remains focused on maintaining growth in its core areas and adapting its strategies to the evolving landscape.